NuCana is a clinical stage biopharmaceutical company developing and commercialising novel anti-cancer medicines.

With its next generation of anti-cancer agents (nucleotide analogues), NuCana is setting new benchmarks for innovative therapeutic treatments. The state-of-the-art ProTide technology transforms existing therapies into better and safer medicines that overcome key cancer resistance mechanisms.

Company Growth (employees)
Type
Public
HQ
Edinburgh, GB
Founded
2008
Size (employees)
20 (est)+6%
NuCana was founded in 2008 and is headquartered in Edinburgh, GB

Key People/Management at NuCana

Hugh S. Griffith

Hugh S. Griffith

Co-Founder, CEO & Board Member
Ian Abercrombie

Ian Abercrombie

Business Unit Director
Chris Wood

Chris Wood

Executive Chairman & Medical Director

NuCana Office Locations

NuCana has an office in Edinburgh
Edinburgh, GB (HQ)
10 Lochside Place

NuCana Financials and Metrics

NuCana Financials

GBP

Net income (FY, 2016)

(6 m)

EBITDA (FY, 2016)

(8.3 m)

EBIT (FY, 2016)

(8.4 m)

Cash (31-Dec-2016)

20 m
GBPFY, 2014FY, 2015FY, 2016

EBITDA

(6.9 m)(8.3 m)

EBIT

(6.9 m)(8.4 m)

Pre tax profit

(3.7 m)(6.5 m)(8.2 m)

Income tax expense

587.6 k1.2 m2.1 m
GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

117.1 k3.2 k759.2 k1 m6.4 m4.9 m36.4 m29.2 m20 m

Accounts Receivable

42.3 k17.3 k185.8 k385.2 k561.8 k511.7 k639.5 k148.8 k21 k

Inventories

365.7 k

Current Assets

159.4 k386.1 k945 k1.4 m6.9 m5.4 m37.1 m30.7 m25.8 m
    GBPFY, 2014FY, 2015FY, 2016

    Net Income

    (3.1 m)(5.3 m)(6 m)

    Cash From Operating Activities

    (2.6 m)(4.5 m)(9.3 m)

    Cash From Financing Activities

    199.9 k

    Net Change in Cash

    (2.7 m)(4.6 m)5.9 m
      Y, 2016

      Financial Leverage

      1.1 x
      Show all financial metrics

      Traffic Overview of NuCana

      NuCana Online and Social Media Presence

      NuCana Company Life and Culture

      You may also be interested in